115370 Results

People

  1. Ladanyi
    Ladanyi
  2. Motzer
    Motzer
  3. Reuter
    Reuter
  4. Scher
    Scher
  5. Brennan
    Brennan
  6. Giralt
    Giralt
  7. Gonen
    Gonen
  8. Perales
    Perales
  9. Hudis
    Hudis
  10. Jarnagin
    Jarnagin

Groups

  1. Department of Medicine (39031)
  2. GSK Faculty (22466)
  3. Solid Tumor Oncology Division (22055)
  4. Surgery (21246)
  5. Sloan Kettering Institute Faculty (16085)
  6. Survivorship Research (15761)
  7. Center for Hematologic Malignancies (13261)
  8. Hematologic Malignancies, Division of (13086)
  9. Sloan Kettering Institute Postdocs (12935)
  10. Department of Pathology and Laboratory Medicine (12608)
Formats
  1. Journal Article (66746)
  2. Meeting Abstract (33620)
  3. Book Section (5027)
  4. Review (3744)
  5. Editorial (2162)
  6. Conference Paper (1525)
  7. Correspondence (661)
  8. Guidelines (660)
  9. Research Letter (548)
  10. Miscellaneous (339)
  11. Book Whole (338)
Groups
  1. Department of Medicine (39031)
  2. GSK Faculty (22466)
  3. Solid Tumor Oncology Division (22055)
  4. Surgery (21246)
  5. Sloan Kettering Institute Faculty (16085)
  6. Survivorship Research (15761)

More Groups

People
  1. Marc Ladanyi (1326)
  2. Robert Motzer (1243)
  3. Victor Reuter (1228)
  4. Howard Scher (1130)
  5. Murray Brennan (1059)
  6. Sergio Giralt (1049)

More People

Years
  1. 2025 (1982)
  2. 2024 (5377)
  3. 2023 (5804)
  4. 2022 (6168)
  5. 2021 (5712)
  6. 2020 (5598)

More Years

Publications
  1. Journal of Clinical Oncology (8590)
  2. Blood (4950)
  3. Cancer Research (2701)
  4. International Journal of Radiation Oncology, Biology, Physics (2610)
  5. Laboratory Investigation (1879)
  6. Modern Pathology (1812)

More Publications

Publishers
  1. Elsevier Inc. (13855)
  2. American Society of Clinical Oncology (9157)
  3. Springer (7152)
  4. Nature Publishing Group (6367)
  5. American Association for Cancer Research (6002)
  6. Elsevier Science, Inc. (5503)

More Publishers

Results (115370)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Preliminary efficacy and safety of disitamab vedotin (DV) with pembrolizumab (P) in treatment (Tx)-naive HER2- expressing, locally advanced or metastatic urothelial carcinoma (la/mUC): RC48G001 cohort C
    Meeting Abstract

    Galsky, M. D.; Koshkin, V. S.; Campbell, M. T.; Drakaki, A.; Bowman, I.; Rose, A. A. N.; Brown, J. R.; Aragon-Ching, J. B.; Gadde, S.; Harandi, A.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Phase II study of PDR001 in combination with MAPK pathway inhibitors in patients with radioactive-refractory differentiated thyroid cancer (DTC)
    Meeting Abstract

    Wong, W.; Sherman, E. J.; Kriplani, A.; Michel, L.; Zhi, I.; Hung, T. K. W.; Dunn, L.; Grewal, R. K.; Krishnamoorthy, G.; Ostrovnaya, I.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Phase I trial of adjuvant pembrolizumab after radiation therapy for lung-intact malignant pleural mesothelioma
    Meeting Abstract

    Ning, M. S.; Gandhi, S.; Gomez, D. R.; Chang, J. Y.; Blumenschein, G.; Rice, D.; O'Reilly, M.; Sepesi, B.; Lin, S. H. H.; Liao, Z.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • ARTIMES: Automated response evaluation to treatment in mesothelioma
    Meeting Abstract

    Groot Lipman, K. B. W; Wittenberg, R.; de Oliveira Taveira, M.; Smesseim, I.; Schmitz, A.; Boellaard, T.; Chupetlovska, K.; Abdelatty Elsayed, M.; Petrychenko, L.; Jain, N.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Intracranial response in patients (pts) with baseline (BL) brain metastases (BM) and extensive-stage (ES) small cell lung cancer (SCLC) treated with ifinatamab deruxtecan (I-DXd) in the IDeate-Lung01 study
    Meeting Abstract

    Johnson, M. L.; Simoes da Rocha, P. F.; Kim, Y. J.; Chen, Y.; Paz-Ares, L. G.; Girard, N.; Hann, C. L.; Nishio, M.; Ahn, M. J.; Qian, M.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • IDeate-Lung03: A Phase Ib/II study of ifinatamab deruxtecan (I-DXd) plus atezolizumab (atezo) with or without carboplatin (carbo) as first-line (1L) induction or maintenance in patients (pts) with extensive stage (ES) small cell lung cancer (SCLC)
    Meeting Abstract

    Rudin, C. M.; Salkeni, M. A.; Gutierrez, M.; Hayashi, H.; Thompson, J.; Arca, M.; Hirose, D.; Singh, J.; Turner, J.; Zhang, Y.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Peripheral blood (PB) T cell phenotype and tumor microenvironment (TME) subtype are independently associated with immune checkpoint blockade (ICB) outcomes in sarcomas
    Meeting Abstract

    Rosenbaum, E.; Ehrich, F.; Bradic, M.; Kelly, C. M.; Movva, S.; Chan, J.; Chi, P.; Banks, L.; Dickson, M.; Keohan, M. L.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Safety, efficacy, and patient-reported outcomes (PROs) with vimseltinib in patients (pts) with tenosynovial giant cell tumor (TGCT) who received prior antiecolony-stimulating factor 1 (CSF1) therapy: Ongoing phase II study
    Meeting Abstract

    D'Amato, G.; Wagner, A. J.; Ganjoo, K. N.; Stacchiotti, S.; Gelderblom, H.; Ryan, C. W.; Palmerini, E.; Ravi, V.; Saleh, R.; Le Cesne, A.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Safety and efficacy with vimseltinib in patients (pts) with tenosynovial giant cell tumor (TGCT) who received no prior antiecolony-stimulating factor 1 (CSF1) therapy: Ongoing phase II study
    Meeting Abstract

    Serrano, C.; Blay, J. Y.; Rutkowski, P.; Gelderblom, H.; Stacchiotti, S.; Falcon Gonzalez, A.; Desai, J.; Le Cesne, A.; Ferraresi, V.; Palmerini, E.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Updated results of the RINGSIDE phase II trial and open-label extension of AL102 for treatment of desmoid tumors
    Meeting Abstract

    Kasper, B.; Gounder, M.; Chugh, R.; Singh, A.; Van Tine, B. A.; Andelkovic, V.; Choy, E.; Lewin, J.; Ratan, R.; Yovell, J.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save